<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132878">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991678</url>
  </required_header>
  <id_info>
    <org_study_id>12-102-13</org_study_id>
    <nct_id>NCT01991678</nct_id>
  </id_info>
  <brief_title>A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)</brief_title>
  <official_title>An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nektar Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nektar Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with
      mild or moderate hepatic impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety and PK data from patients with mild or moderate hepatic impairment will be compared
      with a control group consisting of patients with normal hepatic function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of NKTR-102 and its metabolites</measure>
    <time_frame>Day 1 through Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>1 pre-dose PK measurements 14 post-dose PK measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of NKTR-102</measure>
    <time_frame>Day 1 through Day 42</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessments are: physical examinations, vital signs, ECGs, AEs, and laboratory testing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Patients will receive a 90-minute IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mild hepatic dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Patients will receive a 90-minute IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate hepatic dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Patients will receive a 90-minute IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>145 mg/m2 NKTR 102</intervention_name>
    <arm_group_label>normal hepatic function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120 mg/m2 NKTR 102</intervention_name>
    <arm_group_label>mild hepatic dysfunction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>95 mg/m2 NKTR 102</intervention_name>
    <arm_group_label>moderate hepatic dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or progressive advanced solid tumor malignancies

          -  Measurable or non-measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Life expectancy greater than 3 months

          -  Resolution of all acute toxic effects of prior chemotherapy,  and other cancer
             treatments

          -  Adequate bone morrow and kidney function

          -  No signs of decompensated liver cirrhosis or ascites requiring therapeutic
             paracentesis

          -  Agree to use adequate contraception

        Exclusion Criteria:

          -  Previous chemotherapy, immunotherapy, chemo-embolization, targeted therapy or
             investigational agent for malignancy within 4 weeks prior to day 1

          -  Cytochrome P450 CYP3A4 inducers and inhibitors within 4 weeks prior to day 1

          -  Intake of grapefruit, grapefruit juice, Seville oranges, or other products containing
             grapefruit or Seville oranges within 14 days prior to day 1

          -  UGT1A1 genotype of TA 7 in both alleles (homozygous UGT1A1*28) or TA 8 in either one
             or both alleles (hetero- or homozygous for UGT1A1*37)

          -  Major surgery within 4 weeks prior to day 1

          -  Undergone a liver or other organ transplant

          -  Concurrent treatment with other anti-cancer therapy

          -  Untreated central nervous system metastases

          -  Ongoing or active infection

          -  Chronic or acute GI disorders resulting in diarrhea

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charleen Jue</last_name>
    <role>Study Director</role>
    <affiliation>Nektar Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charleen Jue</last_name>
    <phone>415-482-5300</phone>
  </overall_contact>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeno Ashai</last_name>
      <phone>323-865-0463</phone>
      <email>Zeno.Ashai@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Fiermonte, MD</last_name>
      <phone>415-885-7605</phone>
      <email>fiermontep@cc.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Munster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie McCann</last_name>
      <phone>612-626-2569</phone>
      <email>mcca0313@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Greeno, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Norris, MD</last_name>
      <phone>216-844-3345</phone>
      <email>Robin.Norris@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Robin Norris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
